Vasostatin-I, a chromogranin A-derived peptide, in non-selected critically ill patients: Distribution, kinetics, and prognostic significance

Intensive Care Medicine

Volumn 38, Issue 9, 2012, Pages 1514-1522

  Schneider, Francis ^a   Bach, Charlotte ^b   Chung, Hélène ^c   Crippa, Luca ^f   Lavaux, Thomas ^b   Bollaert, Pierre Edouard ^d   Wolff, Michel ^e   Corti, Angelo ^f   Launoy, Anne ^g   Delabranche, Xavier ^a   Lavigne, Thierry ^a   Meyer, Nicolas ^b   Garnero, Patrick ^c   Metz Boutigue, Marie Hélène ^b,h  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Université de Nancy ^*  (France)

^d UNIVERSITÉ DE LORRAINE   (France)

^e BICHAT HOSPITAL   (France)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g HÔPITAL DE HAUTEPIERRE   (France)

^h INSERM   (France)

Author keywords

Chromogranin A; Critically ill; Lactate; Outcome; SAPS II; Vasostatin

Indexed keywords

CHROMOGRANIN A; LACTIC ACID; UNCLASSIFIED DRUG; VASOSTATIN 1;

ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; SHOCK; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOLOGICAL MARKERS; CHROMOGRANIN A; CRITICAL ILLNESS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 84866739109     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-012-2611-3     Document Type: Article

References (34)

1. Banks P, Helle KB (1965) The release of proteins from the stimulated adrenal medulla. Biochem J 97:40C-41C
2. Helle KB, Corti A, Metz-Boutigue MH, Tota B (2007) The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 64:2863-2886
3. Metz-Boutigue MH, Garcia-Sablone P, Hogue-Angeletti R, Aunis D (1993) Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. Eur J Biochem 217:247-257
4. Aardal S, Helle KB (1992) The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 41:9-18
5. Aardal S, Helle K, Elsayed S, Reed R, Serck-Hanssen G (1993) Vasostatins, comprising the N-terminal domain of chromogranin A, supress tension in isolated human blood vessel segments. J Neuroendocrinol 5:405-412
6. Tota B, Quintieri AM, Di Felice V, Cerra MC (2007) New biological aspects of chromogranin A-derived peptides: focus on vasostatins. Comp Biochem Physiol A Physiol 147:11-18
7. Tota B, Cerra MC, Gattuso A (2010) Catecholamines, cardiac natriuretic peptides and chromogranin A: evolution and physiopathology of a "whip-brake" system of the endocrine heart. J Exp Biol 213:3081-3103
8. Lugardon K, Raffner R, Goumon Y, Corti A, Delmas A, Bulet P, Aunis D, Metz-Boutigue MH (2000) Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem 275:10745-10753
9. Bone RC (2008) Towards an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 268:3452-3455
10. Wortsman J, Frank S, Cryer PE (1984) Adrenomedullary response to maximal stress in humans. Am J Med 77:779-784
11. Zhang D, Lavaux T, Voegeli AC, Lavigne T, Castelain V, Meyer N, Sapin R, Aunis D, Metz-Boutigue MH, Schneider F (2008) Prognostic Value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin Chem 54:1497-1503
12. Pachot A, Lepape A, Vey S, Bienvenu J, Mougin B, Monneret G (2006) Systemic transcriptional analysis in survivor and non-survivor septic shock patients: a preliminary study. Immunol Lett 106:63-71
13. Dulhunty JM, Lipman J, Finfer S Sepsis Study Investigators for the ANZICS Clinical Trials Group (2008) Does severe non-infectious SIRS differ from severe sepsis? Results from a multicentre Australian and New Zealand intensive care unit study. Intensive Care Med 34:1654-1661
14. Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957-2963
15. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Belloci F, Crea F, Maseri A (2007) Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 28:1117-1127
16. Degorce F, Goumon Y, Jacquemart L, Vidaud C, Bellanger L, Pons-Anicet D, Seguin P, Metz-Boutigue MH, Aunis D (1999) A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Brit J Cancer 79:65-71
17. Hanley J, McNeil B (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839-843
18. Corti A, Sanchez LP, Gasparri A, Curnis F, Longhi R, Brandazza A, Siccardi AG, Sidoli A (1997) Production and structure characterisation of recombinant chromogranin A N-terminal fragments (vasostatins)-evidence of dimermonomer equilibria. Eur J Biochem 248:692-699
19. Stridsberg M, Angeletti RH, Helle KB (2000) Characterisation of N-terminal chromogranin A and chromogranin B in mammals by region-specific radioimmunoassays and chromatographic separation methods. J Endocrinol 165:703-714
20. Yoo SH, Lewis MS (1993) Dimerization and tetramerization properties of the C-terminal region of chromogranin A: a thermodynamic analysis. Biochemistry 32:8816-8822
21. Hsiao RJ, Mezger MS, O'Connor D (1990) Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 37:955-964
22. Rosjo H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT, Revera M, Mezzani A, Tognoni G, Tavazzi L, Omland T, GISSI-HF Investigators (2010) Prognostic value of chromogranin A in chronic heart failure: data from th GISSI-heart failure trial. Eur J Heart Fail 12:549-556
23. Hörl WH, Wanner C, Schollmeyer P (1987) Proteinases in catabolism and malnutrition. JPEN 11 (5 suppl):98S-103S
24. Pham C T N (2006) Neutrophil serine proteases: specific regulators of inflammation. Nat Rev 6:541-550
25. Yazdan-Ashoori P, Liaw P, Toltl L, Webb B, Kilmer G, Carter DE, Fraser DD (2011) Elevated plasma matrix metalloproteinases and their tissue inhibitors in patients with severe sepsis. J Crit Care 26:556-565
26. Lauhio A, Hästbacka J, Pettilä V, Tervahartiala T, Karlsson S, Varpula T, Varpula M, Ruokonen E, Sorsa T, Kolo E (2011) Serum MMP-8, -9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res 64:590-594
27. Lee WL, Downey GP (2000) Coagulation inhibitors in sepsis and disseminated intravascular coagulation. Intensive Care Med 26:1701-1706
28. Parmer RJ, Mahata SK, Jiang O, Taupenot L, Gong Y, Mahata M, O'Connors DT, Miles LA (2000) Tissue plasminogen activator and chromaffin cell function. Adv Exp Med Biol 428:179-191
29. Hsiao RJ, Neumann HP, Parmer RJ, Barbosa JA, O'Connor DT (1990) Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Am J Med 88:607-613
30. Groeneveld AB, van Lambalgen TA, Thijs LG (1986) Microvascular permeability in endotoxin and bacterial shock. Acute Care 12:195-218
31. Seidah NG, Chrétien M (1999) Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res 848:45-62
32. Roatta S, Passatore M, Novello M, Colombo B, Dondossola E, Mohammed M, Losano G, Corti A, Helle KB (2011) The chromogranin A-derived N-terminal peptide vasostatin-I: in vivo effects on cardiovascular variables in the rabbit. Regul Pept 168:10-20
33. Trzeciak S, Dellinger RP, Chansky ME, Arnold RC, Schorr C, Milcarek B, Hollenberg SM, Parillo JE (2007) Serum lactate as a predictor of mortality in patients with infection. Intensive Care Med 33:970-977
34. Taupenot L, Harper KL, O'Connor DT (2003) The chromogranin-secretogranin family. N Eng J Med 348:1134-1149